The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

SELLAS Life Sciences Group (SLS) has entered a pivotal moment after its Phase 3 REGAL trial of galinpepimut-S reached the pre ...

SELLAS Life Sciences Group Inc SLS shares are falling Wednesday, pulling back after trading higher earlier in the day, as the ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Shares of SELLAS Life Sciences Group, Inc. ( SLS) are falling 17 percent on Wednesday morning after the company announced that the pivotal Phase 3 REGAL trial evaluating galinpepimut-S in patients ...

Detailed price information for Sellas Life Sciences Group Inc (SLS-Q) from The Globe and Mail including charting and trades.

SELLAS Life Sciences Group, Inc. announced plans to present preclinical data on the efficacy of its cancer therapy SLS009 (tambiciclib) at the upcoming ASCO Annual Meeting, scheduled for May 30 to ...

BlackRock holds 15,872,685 shares of SELLAS Life Sciences Group Inc. common stock. Ownership percentage: This stake accounts ...

Sellas Life Sciences is a late-stage biotech with no product sales, hinging on its Phase 3 REGAL trial for GPS in AML. Click ...

Good morning, and welcome to the SELLAS Life Sciences R&D Day. As a reminder, this call is being recorded, and a replay will be made available on the SELLAS website following the conclusion of the ...

SELLAS Life Sciences Group, Inc. announced positive overall survival results from their ongoing Phase 2 trial of SLS009 (tambiciclib) in patients with relapsed/refractory acute myeloid leukemia (AML), ...